SCHEMBL880481

SCHEMBL880481

COc1ccc(C(=O)Nc2cc(C)nn2-c2nc3ccccc3[nH]2)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.81
ALDH1A1 P00352 5/20 0.81
MAPT P10636 10/20 0.76
SMN1; SMN2 Q16637 6/20 0.76
HTT P42858 6/20 0.72
LMNA P02545 4/20 0.72
MAPK1 P28482 2/20 0.72
NPSR1 Q6W5P4 8/20 0.72
TDP1 Q9NUW8 6/20 0.72
NPC1 O15118 2/20 0.72
RAB9A P51151 2/20 0.72
MEN1 O00255 7/20 0.67
KMT2A Q03164 7/20 0.67
ATM Q13315 2/20 0.67
POLB P06746 2/20 0.66
HPGD P15428 2/20 0.66
CYP1A2 P05177 2/20 0.66
CYP3A4 P08684 2/20 0.66
CYP2C9 P11712 2/20 0.66
CYP2C19 P33261 2/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13522300 0.90 ALDH1A1 (0.88) KDM4EALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL880478 0.88 ALDH1A1 (0.84) KDM4EALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL880412 0.88 ALDH1A1 (0.84) KDM4EALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL14942661 0.87 ADCY1 (0.62) KDM4EALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL880413 0.82 ALDH1A1 (0.77) KDM4EALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL23188271 0.79 ADCY1 (1.00) ADCY1
SCHEMBL880480 0.79 MAPT (1.00) KDM4EALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL23160939 0.78 ADCY1 (0.75) ADCY1DUSP3
SCHEMBL23249615 0.78 SLC2A1 (0.77) ADCY1DUSP3
SCHEMBL10280604 0.78 TDP1 (1.00) KDM4EALDH1A1MAPTSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440705-B2 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2013-05-14 US disclosed
EP-2433634-A2 Compounds, compositions and methods of inhibiting a-synuclein toxicity The Whitehead Institute for Biomedical Research (US) 2012-03-28 EP disclosed
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity SNCA, PARK7, HTT KDM4E 1289/4885ALDH1A1 171/4885MAPT 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.